U.S., Canada Pharma-Bio Capital Project Development Stays Strong Despite Pandemic, an Industrial Info Market Brief

As North America's manufacturing sector deals with COVID-19, pharma-bio capital development remains robust. This cohort is realizing five distinct lessons from the pandemic: 1) Plan ahead -- have a contingency plan in place for any future crisis; 2) Have a wide network of support-supply chains that are being widened, and material stockpiled; 3) Go local when possible --although sometimes more costly, firms are trending toward local suppliers; 4) Leverage AI, automation and robotics, while relying less on the human factor in order to prevent long work stoppages, and; 5) Obtain a scaling plan; the ability to scale up when needed. Industrial Info is tracking more than 900 U.S. and Canadian pharma-bio capital projects that are in the planning or engineered phases in the U.S. with a total investment value of $40 billion.